NO20045535L - Fremgangsmate for a fremme roykeavvenning - Google Patents

Fremgangsmate for a fremme roykeavvenning

Info

Publication number
NO20045535L
NO20045535L NO20045535A NO20045535A NO20045535L NO 20045535 L NO20045535 L NO 20045535L NO 20045535 A NO20045535 A NO 20045535A NO 20045535 A NO20045535 A NO 20045535A NO 20045535 L NO20045535 L NO 20045535L
Authority
NO
Norway
Prior art keywords
smoking cessation
procedure
promoting smoking
promoting
reboxetine
Prior art date
Application number
NO20045535A
Other languages
English (en)
Inventor
Erik Ho Fong Wong
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20045535L publication Critical patent/NO20045535L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Anvendelsen av reboxetin i kombinasjon med et røykeavvenningsforsterkende middel for fremme av røykeavvenning beskrives. Videre beskrives en blanding som omfatter reboxetin og et røykeavvennings-forsterkende middel for bruk til fremme av røykeavvenning. Eksempler på de røykeavvennings-forsterkende midler er nikotin, et antidepressivum, en nikotinreseptorantagonist og en opioidantagonist.
NO20045535A 2002-07-01 2004-12-17 Fremgangsmate for a fremme roykeavvenning NO20045535L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39289302P 2002-07-01 2002-07-01
PCT/US2003/016232 WO2004002463A2 (en) 2002-07-01 2003-06-26 Method of promoting smoking cessation

Publications (1)

Publication Number Publication Date
NO20045535L true NO20045535L (no) 2005-01-27

Family

ID=30000949

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045535A NO20045535L (no) 2002-07-01 2004-12-17 Fremgangsmate for a fremme roykeavvenning

Country Status (22)

Country Link
US (1) US20040102440A1 (no)
EP (1) EP1534254A2 (no)
JP (1) JP2005531631A (no)
CN (1) CN1665511A (no)
AP (1) AP2004003188A0 (no)
AU (1) AU2003253609A1 (no)
BR (1) BR0312293A (no)
CA (1) CA2491549A1 (no)
EA (1) EA200401584A1 (no)
EC (1) ECSP045517A (no)
HR (1) HRP20041194A2 (no)
IL (1) IL165882A0 (no)
IS (1) IS7600A (no)
MA (1) MA27597A1 (no)
MX (1) MXPA05000296A (no)
NO (1) NO20045535L (no)
OA (1) OA12878A (no)
PL (1) PL373620A1 (no)
RS (1) RS115204A (no)
TN (1) TNSN04267A1 (no)
WO (1) WO2004002463A2 (no)
ZA (1) ZA200410339B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
ES2708552T3 (es) 2002-12-20 2019-04-10 Niconovum Ab Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC)
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1896002A4 (en) * 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
JP2010508997A (ja) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド 減量薬を投与するための方法
EP2170274A1 (en) * 2007-07-02 2010-04-07 Technion Research and Development Foundation, Ltd. Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20110046116A1 (en) 2009-08-20 2011-02-24 Cukrowski Walter J Sedative for use during eye surgery
CN102573821A (zh) * 2009-09-30 2012-07-11 哈兰·克莱顿·比利 保持体重的戒烟法及营养补充剂
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
EA201291482A1 (ru) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
DK2858640T3 (da) 2012-06-06 2020-06-29 Nalpropion Pharmaceuticals Llc Sammensætning til anvendelse i en fremgangsmåde til behandling af overvægt og fedme hos patienter med høj cardiovaskulær risiko
EP3057596A4 (en) * 2013-10-14 2017-03-29 Palmaya Pty Ltd Compositions and methods of administering same
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
CN104381577A (zh) * 2014-11-18 2015-03-04 安徽润康保健食品有限公司 一种具有戒烟功能的口香糖

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297346B6 (cs) * 1998-04-09 2006-11-15 Pharmacia & Upjohn Company Pouzití reboxetinu pro výrobu léku k lécbe nervových poruch
DE69922367T2 (de) * 1998-05-08 2005-12-22 Pharmacia & Upjohn Co., Kalamazoo Neue arzneimittelkombinationen aus reboxetin und pindolol
ES2246485T3 (es) * 1999-07-01 2006-02-16 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar la incontinencia.
DE10004547A1 (de) * 2000-02-02 2001-08-09 Liedtke Pharmed Gmbh Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe

Also Published As

Publication number Publication date
OA12878A (en) 2006-09-15
IS7600A (is) 2004-12-16
CN1665511A (zh) 2005-09-07
US20040102440A1 (en) 2004-05-27
MA27597A1 (fr) 2005-11-01
PL373620A1 (en) 2005-09-05
TNSN04267A1 (fr) 2007-03-12
HRP20041194A2 (en) 2005-06-30
ZA200410339B (en) 2006-07-26
EA200401584A1 (ru) 2005-08-25
IL165882A0 (en) 2006-01-15
AP2004003188A0 (en) 2004-12-31
WO2004002463A2 (en) 2004-01-08
WO2004002463A3 (en) 2004-02-19
JP2005531631A (ja) 2005-10-20
BR0312293A (pt) 2005-04-12
EP1534254A2 (en) 2005-06-01
ECSP045517A (es) 2005-03-10
AU2003253609A1 (en) 2004-01-19
RS115204A (en) 2007-02-05
CA2491549A1 (en) 2004-01-08
MXPA05000296A (es) 2005-08-19

Similar Documents

Publication Publication Date Title
NO20045535L (no) Fremgangsmate for a fremme roykeavvenning
DE602005021696D1 (de) Indazolcarbonsäureamidverbindungen
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
NO20051260L (no) Arylsubstituerte diazabicykloalkaner som nikotinacetylcholinagonister
DE60334015D1 (de) Pyridopyrrolizin- und pyridoindolizinderivate
EA200700367A1 (ru) Новые производные 4-бензилиденпиперидина
TNSN07195A1 (en) Potentiators of glutamate receptors
ATE435206T1 (de) Heteroarylsulfonylstilbene als 5-ht2a- antagonisten
PT1543011E (pt) Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
GEP20104962B (en) Fused heterocyclic compounds
NO20052909D0 (no) Tetracyclic 3-substituted indoles having serotonin receptor affinity.
HUP0301122A2 (hu) Gyógyszerkombinációk és gasztrointesztinális rendellenességek kezelésében való alkalmazásuk
MX2007003471A (es) Nueva forma cristalina de clorhidrato de (3-cian-1h-indol-7-il)-[4 -(4-fluorofenetil)-piperazin-1-il]-metanona.
TW200621222A (en) Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
MY146549A (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
NO20062336L (no) Kombinasjoner av kaliumkanalapnere og natriumkanalinhibitorer eller aktive substanser som pavirker natriumkanaler for behandling av smertetilstander
DE60329330D1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
MY140886A (en) Piperazinyl and diazapanyl benzamides and benzthioamides
HUP9800938A2 (hu) NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
DK1861360T3 (da) Pyrrolidin-derivater som histamin-H3-receptorantagonister
EA200601176A1 (ru) 3-цианохинолиновые производные с антипролиферативной активностью
UA87122C2 (ru) Агонисты рецепторов глюкагонподобного пептида-1, их применение и способ получения
NO20072720L (no) Farmasoytiske sammensetninger basert pa NK2-antagonister for pediatrisk bruk

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application